SIDE MEETING

SE015

A safer fairer world: exploring political economy perspectives on emerging infectious diseases; their prevention and control

Meeting Organizer

People’s Health Movement

Contact Person : Bridget Lloyd, blloyd@phmovement.org

30 January 2018
14:00 - 17:30 hrs.
Venue : LOTUS SUITE 14

Open to All Participants

BACKGROUND :

The issues we propose to focus on include: • the role of industrial agriculture and land use changes in the genesis of new infectious diseases; • the role of the pharmaceutical industry in the heightened risk of a post-antibiotic future; • need for global reform of TNC regulation; and • the funding of the Global Health Security Agenda. Most of these issues are familiar to the global public health and one health communities. The exception is our proposal to link them to the wider debates regarding the global regulation of transnational corporations (TNCs) and in particular the work of the open-ended intergovernmental working group on transnational corporations and other business enterprises with respect to human rights.

OBJECTIVES :

The objectives of the proposed side event will be to: • explore the ways in which the globalisation of food systems (including agricultural practice) has contributed to the generation of new infectious diseases and explore the kinds of global regulatory capacity which would be needed to steer food systems development for a safer world; • explore the ways international investment flows, and foreign direct investment in particular, are shaping land use patterns, including deforestation, and the ways these dynamics have impacted on the generation of new infectious diseases and explore the kinds of global regulatory capacity which would be needed to steer investment flows for a safer and fairer world; • explore the role of the international pharmaceutical industry, including its marketing practices, its resistance to effective monitoring and regulation and its R&D priorities, in driving the inappropriate use of antimicrobials and the rising threat of a post-antibiotic world and explore the kinds of global regulatory capacity which may be needed to steer the development of the global pharmaceutical industry for a safer world; • explore the regulatory capacity of the prevailing global governance regime in relation to food systems, foreign direct investment flows and pharmaceutical company practices in the context of extraterritorial obligations associated with existing and proposed human rights instruments, including the proposals emerging from the open-ended intergovernmental working group on transnational corporations and other business enterprises with respect to human rights; and • explore the funding flows and the distribution of costs and benefits, including opportunity costs, associated with the Global Health Security Agenda, having regard to the global dynamics contributing to the threats of zoonoses and of a post-antibiotic world and explore alternative ways of paying for the necessary regulatory and control initiatives.